SC 13G/A 1 ea135034-sc13gaslager_oramed.htm AMENDMENT TO FORM SC 13G

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G/A

 

Under the Securities Exchange Act of 1934
(Amendment No. 1)*

 

ORAMED PHARMACEUTICALS INC.

(Name of Issuer)

 

Common Stock, par value $0.012 per share

(Title of Class of Securities)

 

68403P203

(CUSIP Number)

 

December 31, 2020

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

☐Rule 13d-1(b)

 

☒Rule 13d-1(c)

 

☐Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. 68403P203 13G/A Page 2 of 10 Pages

 

1.

Names of Reporting Persons

Regals Capital Management LP

 

2.

Check the Appropriate Box if a Member of a Group

(See Instructions)

 

(a) ☐

(b) ☐

 

3.

SEC Use Only

 

4.

Citizenship or Place of Organization

Delaware

 

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5.

 

Sole Voting Power

 

0

 

6.

Shared Voting Power

 

1,344,123

 

7.

Sole Dispositive Power

 

0

 

8.

Shared Dispositive Power

 

1,344,123

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,344,123

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

(See Instructions)

 

¨

 

11.

Percent of Class Represented by Amount in Row (9)

 

5.04%

 

 

12.

Type of Reporting Person (See Instructions)

 

IN

 

 

 

 

 

CUSIP No. 68403P203 13G/A Page 3 of 10 Pages

 

1.

Names of Reporting Persons

Regals Fund LP

 

2.

Check the Appropriate Box if a Member of a Group

(See Instructions)

 

(a) ☐

(b) ☐

 

3.

SEC Use Only

 

4.

Citizenship or Place of Organization

Delaware

 

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5.

 

Sole Voting Power

 

0

 

6.

Shared Voting Power

 

1,344,123

 

7.

Sole Dispositive Power

 

0

 

8.

Shared Dispositive Power

 

1,344,123

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,344,123

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

(See Instructions)

 

 

 ¨
11.

Percent of Class Represented by Amount in Row (9)

 

5.04%

 

 

12.

Type of Reporting Person (See Instructions)

 

PN

 

 

 

 

 

CUSIP No. 68403P203 13G/A Page 4 of 10 Pages

 

1.

Names of Reporting Persons

David M. Slager

 

2.

Check the Appropriate Box if a Member of a Group

(See Instructions)

 

(a) ☐

(b) ☐

 

3.

SEC Use Only

 

4.

Citizenship or Place of Organization

Netherlands

 

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5.

 

Sole Voting Power

 

0

 

6.

Shared Voting Power

 

1,344,123

 

7.

Sole Dispositive Power

 

0

 

8.

Shared Dispositive Power

 

1,344,123

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,344,123

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

(See Instructions)

 

 ¨
11.

Percent of Class Represented by Amount in Row (9)

 

5.04%

 

 

12.

Type of Reporting Person (See Instructions)

 

PN

 

 

 

 

 

CUSIP No. 68403P203 13G/A Page 5 of 10 Pages

 

This Amendment No. 1 is filed with respect to shares of Common Stock (as defined below) of Oramed Pharmaceuticals, Inc. beneficially owned by the Reporting Persons (as defined below) as of December 31, 2020, and amends and reinstates the Schedule 13G filed by the Reporting Persons on February 11, 2020.

 

Item 1(a).Name of Issuer

 

Oramed Pharmaceuticals Inc.

 

Item 1(b).Address of Issuer’s Principal Executive Offices

 

1185 Avenue of the Americas, Suite 228, New York, NY 10036.

 

Item 2(a).Name of Person Filing

 

This Schedule is filed on behalf of each of the following Reporting Persons:

 

(1) Regals Capital Management LP (“Regals Management”)

 

(2) Regals Fund LP (“Regals Fund”)

 

(3) David M. Slager (“Mr. Slager”)

 

Item 2(b).Address of Principal Business Offices or, if None, Residence

 

The address of each Reporting Person is:

 

c/o Regals Capital Management LP
152 West 57th Street, 9th Floor
New York, NY 10019

 

Item 2(c).Citizenship

 

Each of Regals Management and Regals Fund is a Delaware limited partnership.

 

Mr. Slager is a citizen of The Netherlands.

 

Item 2(d).Title of Class of Securities

 

Common Stock.

 

Item 2(e).CUSIP Number

 

68403P203

 

Item 3.If the statement is being filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the filing person is a:

 

Not Applicable

 

 

 

 

CUSIP No. 68403P203 13G/A Page 6 of 10 Pages

 

Item 4.Ownership

 

(a) Amount beneficially owned:

 

Each Reporting Person may be deemed to beneficially own 1,344,123 shares of Common Stock of the Issuer, including 20,000 shares underlying currently exercisable shares. Regals Management is the investment manager of Regals Fund, the owner of record of the Common Stock reported in this Schedule. Mr. Slager is the managing member of the general partner of Regals Management. All investment decisions are made by Mr. Slager, and thus the power to vote or direct the votes of these shares of Common Stock, as well as the power to dispose or direct the disposition of such shares of common stock is held by Slager through Regals Management.

 

(b) Percent of class:

 

Each Reporting Person may be deemed to beneficially own 5.04% of the outstanding shares of Common Stock of the Issuer based upon 26,661,004 shares of Common Stock issued and outstanding as of January 14, 2021, as reported in Issuer’s Quarterly Report form 10-Q, filed with the Securities and Exchange Commission on January 14, 2021.

 

(c) Number of shares as to which the person has:

 

(i) Sole power to vote or to direct the vote:

 

Regals Management:   0 
Regals Fund:   0 
Mr. Slager:   0 

 

(ii) Shared power to vote or to direct the vote:

 

Regals Management:   1,344,123 
Regals Fund:   1,344,123 
Mr. Slager:   1,344,123 

 

(iii) Sole power to dispose or to direct the disposition of:

 

Regals Management:   0 
Regals Fund:   0 
Mr. Slager:   0 

 

(iv) Shared power to dispose or to direct the disposition of:

 

Regals Management:   1,344,123 
Regals Fund:   1,344,123 
Mr. Slager:   1,344,123 

 

Reference is made to Item 4(a) above as to the Issuer’s Common Stock that may be deemed to be beneficially owned by the Reporting Persons.

 

Item 5.Ownership of Five Percent or Less of a Class

 

Not Applicable

 

Item 6.Ownership of More Than Five Percent on Behalf of Another Person

 

Not Applicable

 

 

 

 

CUSIP No. 68403P203 13G/A Page 7 of 10 Pages

 

Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

 

Not Applicable

 

Item 8.Identification and Classification of Members of the Group

 

Not Applicable

 

Item 9.Notice of Dissolution of Group

 

Not Applicable

 

Item 10.Certification

 

By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

 

 

 

CUSIP No. 68403P203 13G/A Page 8 of 10 Pages

 

SIGNATURE

 

After reasonable inquiry and to the best of its knowledge and belief, each Reporting Person certifies that the information set forth in this statement is true, complete and correct.

 

Dated:  February 9, 2021 Regals Capital Management LP
  By: Regals Capital Holdings LLC, its general partner
   
  /s/ David M. Slager
  Name: David M. Slager
  Title: Managing Member
   
Dated:  February 9, 2021 Regals Fund LP
  By: Regals Fund GP LLC, its general partner
   
  /s/ David M. Slager
  Name: David M. Slager
  Title: Managing Member
   
Dated:  February 9, 2021 David M. Slager
   
  /s/ David M. Slager
  Name: David M. Slager

 

Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

  

 

 

 

CUSIP No. 68403P203 13G/A Page 9 of 10 Pages

 

EXHIBIT INDEX

 

Exhibit   Description
     
99.1   Agreement of Joint Filing. (Filed herewith)